Pre-market Hot Trades in US Stocks
Oklo is up 3.18% in pre-market. According to recent key news:
<ol>
<li>
On September 17, Oklo's stock price increase reflects market optimism about small reactors, especially in potential applications in AI computing. Nevertheless, execution still faces challenges.
</li>
<li>
On September 16, Oklo announced plans to build a $1.68 billion fuel recovery facility in Tennessee, which drove the stock price up.
</li>
<li>
On September 15, analysts rated Oklo as a moderate buy, with a target price of $72.50, indicating a downside potential of 23.91% from current levels. The nuclear energy industry has significant growth potential, but risks should be monitored.
</li>
</ol>
Top Gainers in Pre-market US Stocks
89bio is up 82.80% in pre-market. According to recent key news:
<ol>
<li>
On September 18, Roche announced it would acquire 89bio for $14.50 per share in cash, with a total transaction value of up to $3.5 billion. This move significantly boosted 89bio's stock price. Data source: Zhitong Finance.
</li>
<li>
On September 18, 89bio's key drug pegozafermin is in late-stage development and is expected to become the best therapy for treating metabolic dysfunction-associated fatty liver disease. This news further enhanced market confidence in 89bio. Data source: Roche statement.
</li>
<li>
On September 18, Wall Street gave 89bio stock a strong buy rating, with an average target price of $27, indicating an upside potential of 234.16%. This rating supported the stock price increase. Data source: TipRanks. The biopharmaceutical industry is active in mergers and acquisitions, attracting market attention.
</li>
</ol>
Aptevo Therapeutics is up 76.60% in pre-market. Based on recent important news:
<ol>
<li>
On September 16, Aptevo Therapeutics announced a 100% remission rate in its Phase 3 RAINIER trial for acute myeloid leukemia (AML), driving the stock price up by 57%. The trial tested Aptevo's CD123 x CD3 bispecific antibody mipletamig in combination with venetoclax and azacitidine.
</li>
<li>
On September 16, Aptevo's trading volume surged, with approximately 34 million shares changing hands, compared to an average of about 165,000 shares over the past three months.
</li>
<li>
On September 17, despite facing financial challenges and bearish technical analysis, Aptevo's positive progress in its oncology pipeline provides potential upside. The biotechnology sector has been active recently.
</li>
</ol>
AquaBounty Technologies is up 54.39% in pre-market. According to recent key news:
<ol>
<li>On September 18, technical analysis showed mixed momentum indicator signals, poor stock valuation, negative earnings per share, and lack of dividends affecting its attractiveness. Improvements in operational efficiency and cash flow management are crucial for enhancing financial health
Market sentiment signals a sell, with a market capitalization of $4.3 million, leading to stock price fluctuations. The biotechnology industry has recently shown volatility</li>
</ol>

OKLO

Birks pre-market down 7.03%; Oklo pre-market up 3.18%; 89bio pre-market up 82.80%; Aptevo Therapeutics pre-market up 76.60%; AquaBounty Technologies pre-market up 54.39%

Pre-market hot trades in US stocks: Birks pre-market down 7.03%; Oklo pre-market up 3.18%